Overview

A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, Phase II, randomized, controlled, open label trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with bevacizumab and paclitaxel in patients who have not previously received chemotherapy for locally recurrent or metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Paclitaxel
Sunitinib